Bank of Qingdao Co., Ltd.* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 青 島 銀 行 股 份 有 限 公 司 * （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （H股股份代號：3866） 2025年第一季度報告 青島銀行股份有限公司（「本行」）根據《香港聯合交易所有限公司證券上市規則》（「上市規 則」）第13.09條及香港法例第571章《證券及期貨條例》第XIVA部項下之內幕消息條文（按 上市規則定義）作出本公告。 本報告以中英文編製，如中英文文本有任何不一致，以中文文本為準。 重要內容提示： - 1 - 1. 本行董事會、監事會及董事、監事、高級管理人員保證季度報告內容的真實、準 確、完整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律 責任。 2. 本行第九屆董事會（「董事會」）第十一次會議於2025年4月28日以通訊表決方式召 開，會議應參與表決董事14名，實 ...

Duiba Group Limited （於開曼群島註冊成立的有限公司） 股份代號：1753 年度報 告 2024 目錄 董事會 執行董事 陳曉亮先生 （董事長兼首席執行官） 朱江波先生 程鵬先生 非執行董事 兌吧集团有限公司（「本公司」，連同其附屬公司統稱「本集團」）於2018年2月在開曼群島註冊成立。其於2019年5月7日在聯 交所主板上市（股份代號：01753.HK），總部位於中國杭州。本集團的使命是成為企業首選的業務運營合夥人，為企業提供 用戶增長、用戶留存及流量變現的全週期服務。 本集團於2014年推出用戶運營SaaS平台及於2015年推出互聯網廣告平台。其為中國領先的用戶運營SaaS供應商及互聯網 廣告平台運營商。 年度報告2024 兌吧集團有限公司 2 2 公司簡介 3 公司資料 5 主席報告書 6 財務及運營資料摘要 8 管理層討論及分析 18 董事會報告 34 企業管治報告 53 董事及高級管理層 57 獨立核數師報告 63 綜合損益及其他全面收益表 64 綜合財務狀況表 66 綜合權益變動表 68 綜合現金流量表 71 財務報表附註 163 釋義 公司簡介 楊佳青女士 （於2024年3月2 ...

Financial Performance - The group's revenue for the year ended December 31, 2024, was RMB 6.635 billion, an increase of 0.4% compared to RMB 6.608 billion in 2023[8]. - The profit attributable to equity shareholders was RMB 733 million, an increase of 2.6% from RMB 715 million in 2023[8]. - Adjusted profit attributable to equity shareholders was RMB 1.018 billion, a significant increase of 41.6% from RMB 719 million in 2023[8]. - Revenue from the neuroscience segment was RMB 2.174 billion, accounting for 32.8% of total revenue, representing a growth of 10.4% from RMB 1.969 billion in 2023[112]. - Revenue from the autoimmune segment was RMB 1.811 billion, making up 27.3% of total revenue, with a significant increase of 28.0% from RMB 1.415 billion in 2023[112]. - Revenue from the oncology segment was RMB 1.298 billion, which accounted for 19.6% of total revenue, showing a decline of 17.6% from RMB 1.576 billion in 2023[112]. - Total R&D expenditure for the year was RMB 1.523 billion, a decrease of 22.3% from RMB 1.960 billion in 2023, with R&D expenditure accounting for 23.0% of revenue, down from 29.7% in 2023[115]. - The net cash generated from operating activities for the year ended December 31, 2024, was RMB 1.391 billion, a substantial increase from RMB 151 million in 2023[119]. - As of December 31, 2024, the company had cash and cash equivalents of RMB 1.943 billion, down from RMB 2.007 billion in 2023[119]. - The current ratio as of December 31, 2024, was 200.4%, slightly down from 209.9% in 2023, while the debt-to-asset ratio increased to 38.6% from 33.5%[120]. Product Development and Pipeline - The group has eight innovative drugs approved for sale and has over 60 innovative drug candidates in its pipeline, with 16 undergoing registration clinical trials[9]. - The company has entered a critical phase for its R&D pipeline, with three new drug molecules in Phase III clinical trials[19]. - The company has made significant progress in clinical trials, with a Phase III trial for Enzashu® achieving its primary endpoint and NDA submitted to NMPA on March 11, 2024[25]. - The company has over 60 innovative drug candidates in its pipeline, with three in the NDA approval process and four in Phase III clinical trials[30]. - The company has received approval for 11 new INDs, including SIM0501 for advanced malignant solid tumors expected in January 2024 and SIM0505 for advanced solid tumors expected in December 2024 in the US and January 2025 in China[23]. - The company has established a partnership with Shenzhen Tajiri Biopharmaceutical Co., Ltd. for the exclusive commercialization rights of TGRX-326 in mainland China, enhancing its lung cancer product portfolio[25]. - The company plans to submit multiple innovative drug applications within the year, including new drugs for ovarian cancer and insomnia, which are expected to drive strong performance growth[12]. - The company is focusing on four key areas: neuroscience, oncology, autoimmune diseases, and anti-infection, while deepening international cooperation to promote more globally innovative drugs[12]. Market and Commercialization - The marketing network covers over 3,000 tertiary hospitals and approximately 17,000 other hospitals and medical institutions across China[9]. - The overseas licensing transaction value for Chinese innovative drugs exceeded $15 billion in 2024, representing a 45% year-on-year increase[13]. - Two products, Kexaila® and Enlituzumab®, were successfully included in the National Reimbursement Drug List (NRDL) in 2024, significantly enhancing patient accessibility and market penetration[16]. - The company has accelerated the clinical entry of its self-developed pipeline, with multiple products entering the key POC data phase[20]. - The company aims to enhance production capacity and efficiency under its "Innovation 2.0" strategy, with a new production base completed in 12 months, exceeding industry averages[28]. Employee and Corporate Governance - As of December 31, 2024, the group had a total of 6,584 full-time employees, with employee costs amounting to RMB 2.127 billion[129]. - The company has established a training academy to provide regular training for employees, including onboarding and skills training[129]. - The company’s employee compensation includes basic salary, performance bonuses, and long-term incentives, with a focus on attracting and retaining talent[129]. - The board approved the grant of a total of 3,828,000 restricted share units on March 21, 2024, and 2,968,100 restricted share units on August 22, 2024, to eligible participants[130]. - The company has appointed independent non-executive directors who have confirmed their independence according to the listing rules[194]. - All executive directors have service contracts with the company, while independent non-executive directors have signed appointment letters for a term of three years[193]. Risks and Challenges - The pharmaceutical industry is highly competitive, and failure to effectively compete may lead to decreased sales, price reductions, and loss of market share[158]. - The company may face challenges in maintaining sales volume, pricing levels, and profit margins for its key products due to various factors[158]. - The development of in-progress products is time-consuming and costly, with uncertain outcomes, which may hinder timely regulatory approvals and commercialization[160]. - The company relies on third parties for oversight and support of in-progress products, and any failure by these parties could delay regulatory approvals[160]. - The company may face increased operational costs or inability to fulfill customer orders due to failure to maintain optimal inventory levels[161]. - The company is exposed to risks related to the quality and production processes of third-party manufactured products, which may not consistently meet necessary quality standards[160]. Shareholder and Financial Activities - The company declared a final dividend of RMB 0.16 per share for the year ended December 31, 2024, totaling approximately RMB 397.81 million[135]. - The company raised RMB 970 million through a capital increase agreement, which will result in approximately 11.45% of the enlarged issued share capital being held by new investors[127]. - The company repurchased a total of 130,402,000 shares at a total cost of HKD 753,736,820 during the period from January 1, 2024, to December 31, 2024[146]. - The board believes that the share repurchase demonstrates confidence in the company's business prospects and will ultimately create value for shareholders[147]. - The company has not made any changes to its main business operations during the reporting year[134].

（於中華人民共和國註冊成立的股份有限公司） （H 股股份代號：3866） 年度報告 2024 目錄 | 第一節 | 重要提示、目錄和釋義 | 2 | | --- | --- | --- | | 第二節 | 公司簡介和主要財務指標 | 5 | | 第三節 | 董事長致辭 | 12 | | 第四節 | 行長致辭 | 14 | | 第五節 | 管理層討論與分析 | 16 | | 第六節 | 公司治理 | 94 | | 第七節 | 環境和社會責任 | 148 | | 第八節 | 重要事項 | 150 | | 第九節 | 股份變動及股東情況 | 164 | | 第十節 | 優先股相關情況 | 176 | | 第十一節 | 董事會報告 | 177 | | 第十二節 | 監事會報告 | 184 | | 第十三節 | 獨立審計師報告 | 185 | | 第十四節 | 財務報表附註 | 201 | | 第十五節 | 未經審計的補充財務資料 | 321 | 青島銀行股份有限公司 2024 年度報告 1 第一節 重要提示、目錄和釋義 青島銀行股份有限公司 2024 年度報告 2 1. 本行董事會、監事會及董事、監事、高級管理人員保 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 截至二零二五年三月三十一日止三個月 未經審計之合併業績 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09條及香港 法例第571章《證 券 及 期 貨 條 例》第XIVA部 項 下 內 幕 消 息 條 文 作 出。 龍 源 電 力 集 團 股 份 有 限 公 司（「本公司」）及 其 附 屬 公 司（「本集團」）截 至 二 零 二 五 年 三 月 三 十 一 日 止 三 個 月 未 經 審 計 之 合 併 業 績 如 下。 截 至 二 零 二 五 年 三 月 三 十 一 日 止 三 個 月，本 集 團 收 入 人 民 幣81.40億 元， 比去年同期持續經營收入增長0.92%，其中，風電分部收入人民幣73.68億元， 比去年同期 減 少1.89%，光伏分部收入人民幣7.15億 元，比 去 年 同 期 增 長 43.09%，其 他 ...

Contents 目錄 | | Pages | | --- | --- | | | 頁次 | | Corporate Information | 2 | | 公司資料 | | | Chairman's Statement | 5 | | 主席報告 | | | Management Discussion and Analysis | 18 | | 管理層討論及分析 | | | Corporate Governance Report | 29 | | 企業管治報告 | | | Report of the Directors | 54 | | 董事會報告 | | | Independent Auditors' Report | 71 | | 獨立核數師報告 | | | Consolidated Statement of Profit or Loss and Other Comprehensive Income | 77 | | 綜合損益及其他全面收益表 | | | Consolidated Statement of Financial Position | 78 | | 綜合財務狀況表 | | | Consolid ...

Financial Performance - The company's revenue for 2024 reached RMB 12,260,814, an increase of 21.4% compared to RMB 10,103,806 in 2023[9] - Gross profit for 2024 was RMB 11,155,406, reflecting a gross margin of approximately 91%[9] - The company reported a net profit of RMB 4,371,825 for 2024, up 33.4% from RMB 3,277,503 in 2023[9] - The company recorded a revenue of approximately RMB 12.261 billion for the year ending December 31, 2024, representing a year-on-year growth of about 21.3%[22] - Profit for the same period was approximately RMB 4.372 billion, an increase of about 33.4% compared to the previous year[22] - The company achieved a basic earnings per share of approximately RMB 0.74, reflecting a year-on-year increase of about 33.3%[22] Assets and Liabilities - Total assets as of 2024 amounted to RMB 31,657,849, while total liabilities decreased to RMB 2,977,935[9] - The asset-liability ratio was approximately 9.4% as of December 31, 2024, down from 21.9% the previous year[61] - The company maintained a cash and bank deposit balance of RMB 22.622 billion as of December 31, 2024, compared to RMB 22.435 billion a year earlier[61] Research and Development - Research and development expenses for 2024 were RMB 2,701,650, representing a significant investment in innovation[9] - The company is conducting over 60 clinical trials for innovative drugs, with 8 new candidates entering clinical research stages during the reporting period[38] - The company has established a robust R&D platform with over 1,800 researchers across multiple centers, focusing on innovative drug development[37] - The company plans to continue increasing R&D investments due to market changes and innovation efforts[141] Product Development and Approvals - The company received clinical trial approval for its new drug HS-10501, aimed at treating type 2 diabetes and adult obesity[11] - A licensing agreement was established with Pumis for the global development and commercialization of HS-20117, a bispecific ADC product[11] - The company has submitted multiple New Drug Applications (NDAs) for its innovative drug Amelior, targeting specific NSCLC patient populations[12] - The company received breakthrough therapy designation from the FDA for GSK5764227 (HS-20093) for the treatment of ES-SCLC patients[13] - The company’s innovative drug HS-20110 received clinical trial approval from NMPA for advanced solid tumors[14] - The company’s innovative drugs have all been included in the national medical insurance catalog as of December 31, 2024[24] Market Strategy and Partnerships - The company aims to expand its market presence through strategic partnerships and new product developments in the coming years[11] - The company will continue to focus on innovative drug development and internationalization strategies, particularly in oncology, central nervous system, metabolism, and autoimmune disease treatment areas[82] - The company plans to strengthen business development collaborations to optimize its global market layout[82] Corporate Governance - The board of directors consists of three executive directors and three independent non-executive directors as of December 31, 2024[87] - The company has established five specialized committees within the board to oversee various aspects of governance, including audit and remuneration[85] - The company has adopted a high standard of corporate governance to protect shareholder interests and enhance corporate value[84] Risk Management - The company identified major risks including industry competition and technological changes, emphasizing the need for continuous R&D investment to maintain product competitiveness[74] - Regulatory changes in the Chinese pharmaceutical industry may pose challenges to short-term business operations and cost structures, requiring the company to adapt to new regulations[75] - The company employs risk assessment tools such as risk matrices and sensitivity analysis to scientifically classify risks and implement corresponding control strategies[81] Employee and Talent Management - Attracting and retaining key talent is critical for enhancing organizational capabilities, with established mechanisms for talent retention and training[80] - The group’s employees are considered the most valuable asset, with compensation linked to performance and regular training provided to enhance productivity[153] Environmental, Social, and Governance (ESG) - The company maintained an MSCI ESG rating of AA and ranked first in the S&P Global Corporate Sustainability Assessment for the Chinese pharmaceutical industry[15][17] - The company is committed to identifying and mapping climate risks to its future strategies and business activities, focusing on carbon neutrality goals[81] - The group plans to publish an Environmental, Social, and Governance (ESG) report in conjunction with its annual report, as per listing rules[151] Shareholder Information - The company reported a proposed final dividend of HKD 0.1353 per share for the year ending December 31, 2024, compared to HKD 0.1422 in 2023, resulting in a total annual dividend of HKD 0.3363 per share[132] - As of December 31, 2024, major shareholders include Stellar Infinity and Sunrise Investment, each holding 3,900,000,000 shares, representing 65.70% of the total shares[170] Financial Management - The company has established a robust internal control system and conducted an annual review of its risk management and internal control systems, which the board believes are effective and adequate[121] - The company has adopted a dividend policy that considers its operating performance, cash flow, financial condition, and other relevant factors when declaring dividends[129]

202 4 年報 年 報 2024 Annual Report 2024 A nnu al R e p ort 目錄 | 主要產品 | 2 | | --- | --- | | 公司資料 | 4 | | 主席報告 | 6 | | 管理層討論及分析 | 12 | | 企業管治報告 | 22 | | 環境、社會及管治報告書 | 35 | | 審核委員會報告 | 66 | | 董事及高級管理層 | 68 | | 董事會報告 | 72 | | 獨立核數師報告 | 93 | | 綜合損益及其他全面收益表 | 99 | | 綜合財務狀況表 | 100 | | 綜合權益變動表 | 102 | | 綜合現金流量表 | 103 | | 綜合財務報表附註 | 105 | | 財務概要 | 200 | 塗布白面牛卡紙為一種將塗料塗佈到 已漂白上層組成的多層紙張構成的白 面牛卡紙。該塗料使白面牛卡紙色澤 更鮮明及更有光澤，令印刷更優質， 同時具備一流的輸墨質素。輕塗白面 牛卡紙的塗布層遠較傳統塗布白板紙 的塗布層為薄，故被認為更環保。 紙 管 原 紙 為 用 作 生 產「紙 芯」的 主 要 材 料，管芯一紙管原紙系列一般用作多種 產品 ...

CANGGANG RAILWAY LIMITED 滄港鐵路有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） Stock code 股份代號 : 2169 年 報 ANNUAL REPORT 2024 Contents 目錄 2 Corporate Information 公司資料 5 Definitions and Glossary 釋義及詞彙 9 Chairman's Statement 董事會主席報告 13 Management Discussion and Analysis 管理層討論及分析 19 Board of Directors and Senior Management 董事會及高級管理層 23 Corporate Governance Report 企業管治報告 45 Environmental, Social and Governance Report 環境、社會及管治報告 85 Report of the Directors 董事會報告 107 Independent Audi ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 168 一、重要提示 - 1 - 1.1 公司董事會、監事會及董事、監事、高級管理人員保證季度報告內容的真實、準 確、完整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律 責任。 1.2 公司第十屆董事會第二十一次會議（「會議」）以書面議案會議方式審議通過季度報 告。會議應參加表決董事7人，實際參加表決董事7人。 1.3 本季度報告中，除內容特別指明外，貨幣皆為人民幣。 1.4 公司法定代表人姜宗祥、主管會計工作負責人侯秋燕及會計機構負責人（會計主管人 員）孫卓晗保證季度報告中財務報表的真實、準確、完整。 1.5 公司季度報告已經公司董事會審計與內控委員會審閱，但未經審計。 二、主要財務數據 （一）主要會計數據和財務指標 單位：元 幣種：人民幣 本報告期比 上年同期增減 2025年第一季度報告 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)及13.10B ...